Detjen, K.M.; Otto, R.; Giesecke, Y.; Geisler, L.; Riemer, P.; Jann, H.; Grötzinger, C.; Sers, C.; Pascher, A.; Lüdde, T.;
et al. Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers 2021, 13, 4463.
https://doi.org/10.3390/cancers13174463
AMA Style
Detjen KM, Otto R, Giesecke Y, Geisler L, Riemer P, Jann H, Grötzinger C, Sers C, Pascher A, Lüdde T,
et al. Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers. 2021; 13(17):4463.
https://doi.org/10.3390/cancers13174463
Chicago/Turabian Style
Detjen, Katharina M., Raik Otto, Yvonne Giesecke, Lukas Geisler, Pamela Riemer, Henning Jann, Carsten Grötzinger, Christine Sers, Andreas Pascher, Tom Lüdde,
and et al. 2021. "Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms" Cancers 13, no. 17: 4463.
https://doi.org/10.3390/cancers13174463
APA Style
Detjen, K. M., Otto, R., Giesecke, Y., Geisler, L., Riemer, P., Jann, H., Grötzinger, C., Sers, C., Pascher, A., Lüdde, T., Leser, U., Wiedenmann, B., Sigal, M., Tacke, F., Roderburg, C., & Hammerich, L.
(2021). Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers, 13(17), 4463.
https://doi.org/10.3390/cancers13174463
